CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 20, 2009
Result type: Reports
Project Number: SR0162-000
Product Line: Reimbursement Review

Generic Name: Pregabalin

Brand Name: Lyrica

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: diabetic peripheral neuropathy

Indications: diabetic peripheral neuropathy

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: September 23, 2009

Recommendation Type: Do not list